【摘要】 宫颈癌是威胁中国女性，乃至全球女性最常见的女性恶性肿瘤之一。由于大多数局部晚期宫颈癌患者确诊时已无手术机会，只能接受放化疗，完成综合治疗后，其5年生存率约为70%,骨盆和腹腔淋巴结受累患者的5年生存率分别为34%和12%。改善患者生存质量并延长其生存时间，对晚期及复发的宫颈癌患者极为重要，由此，宫颈癌的免疫治疗已成为当下研究的热点。宫颈癌免疫疗法在临床上取得了令人瞩目的成效，相关的临床研究也都证实了接受免疫治疗的宫颈癌患者有临床获益。该综述将对宫颈癌免疫治疗的研究进展进行总结。更多还原

【Abstract】 Cervical cancer is one of the most common female malignant tumors that threaten Chinese women and even women worldwide.Due to the lack of surgical options for most locally advanced cervical cancer patients at the time of diagnosis, they can only undergo radiotherapy and chemotherapy.After completing comprehensive treatment, the 5-year survival rate is about 70%,and the 5-year survival rates for patients with pelvic and abdominal lymph node involvement are 34% and 12% respectively.Improving the quality of life and prolonging the survival time of patients is extremely important for advanced and recurrent cervical cancer patients.Therefore, immunotherapy for cervical cancer has become a hot topic in current research.Immunotherapy for cervical cancer has achieved remarkable results in clinical practice, and related clinical studies have confirmed the clinical benefits of immunotherapy in cervical cancer patients.This review will summarize the research progress of immunotherapy for cervical cancer.更多还原